Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – The psychostimulant modafinil is no better than a placebo in improving fatigue, depression and cognitive function in patients with primary brain tumors (PBT),…
Prevention and treatment of cardiovascular disease usually includes taking a variety of medications regularly. However, even after experiencing a heart attack or stroke many patients do not take…
NEW YORK (Reuters Health) – After surgery for stage III colon cancer, adjuvant chemotherapy reduces the risk of distant recurrence by about half, and elderly patients benefit to…
NEW YORK (Reuters Health) – The addition of bevacizumab to adjuvant chemotherapy does not improve invasive disease-free rates in women after resection of breast cancer that’s negative for…
By Will Boggs, MD NEW YORK (Reuters Health) – Patients with unresectable primary spinal sarcoma may benefit from carbon ion radiotherapy (CIRT), Japanese researchers say. Compared with proton…
Hepatitis C is a virus that causes liver inflammation. If not treated effectively it can lead to cirrhosis, liver failure, and even death. A new study tested whether…
Ever wondered what you and your patients were really getting from the Patient Protection and Affordable Care Act? A new blog by NYC neurologist, Dr. Anthony Geraci, explores…
Jay S. Duker, MD, Director of the New England Eye Center, discusses the unmet need for patients with wet and dry macular degeneration. Dr. Duker discusses alternative forms of…
Jay S. Duker, MD, Director of the New England Eye Center, discusses the AREDS studies, which aimed to determine the causes of age-related macular degeneration and the modification of those…
NEW YORK (Reuters Health) – Bevacizumab appears to be most effective for metastatic colorectal cancer when the primary tumor originates distally, according to a Danish study. However, the…